
During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…... [Read More]
During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…... [Read More]
• By David Douglas
NEW YORK (Reuters Health)—In patients with psoriasis and psoriatic arthritis, the incidence of atrial fibrillation and major adverse cardiovascular events does not differ between treatment with ustekinumab and TNF inhibitors, according to a large observational study. “Given a high cardiovascular risk among patients with psoriasis and psoriatic arthritis,” Seoyoung C. Kim, MD, ScD, MSCE, told… [Read More]
The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…... [Read More]
According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…... [Read More]
New clinical trials are underway to determine the safety and efficacy of piclidenoson for patients with plaque psoriasis and rheumatoid arthritis…... [Read More]
• By Lara C. Pullen, PhD
The National Psoriasis Foundation says weight loss and other dietary interventions may benefit psoriasis patients. New recommendations note the benefits of a gluten-free diet for patients who test positive for gluten sensitivity, but also found little evidence to support the use of fish oil supplements for psoriasis patients…... [Read More]
The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…... [Read More]
• By Marilynn Larkin
NEW YORK (Reuters Health)—New recommendations from the National Psoriasis Foundation Medical Board suggest that losing weight by following a low-calorie diet can reduce psoriasisseverity in overweight patients, but there is little evidence to support other dietary interventions. “Our psoriasis patients have long asked us about the role of diet on psoriasis,” Dr. April Armstrong of the… [Read More]
On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…... [Read More]
Ixekizumab is the first agent approved by the FDA for treating plaque psoriasis to include labeling for psoriasis in the genital area…... [Read More]
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.